Abstract

Background: Nociceptin is a 17 amino acid peptide that produces physiological effects through activation of the ORL1 (NOP) receptor. We have identified a novel NOP antagonist (Cpd 1) and found it to have high binding affinity (Ki = 0.11 nM), antagonist potency (Kb = 0.17 nM) and selectivity for NOP. Cpd 1 is orally active, CNS penetrant and potently occupies NOP receptors in vivo. Herein, the effects of Cpd 1 on feeding behavior and metabolism were studied.Methods: Male, lean and dietary‐induced obese (DIO) rats, DIO mice and NOP knockout (KO) mice were used in feeding and indirect calorimetry studies.Results: Consistent with the literature, Cpd 1 reduced food intake in rodents. In lean rats, Cpd 1 inhibited consumption of a highly palatable (high fat/sucrose) diet, reducing the calorie intake to control chow levels. In DIO rats, Cpd 1 inhibited feeding induced by a mild caloric restriction. In DIO mice, Cpd 1 decreased 24 hr free access food intake and decreased the respiratory quotient indicating that metabolism was driven by fat utilization. Fasting‐induced feeding was inhibited by Cpd 1 in 129S6 mice, an effect that was absent in NOP KO mice. Moreover, under vehicle conditions fasting‐induced feeding was reduced in NOP KO mice.Conclusions: These data support that Cpd 1 potently inhibits feeding behavior and stimulates fat utilization in rodents. Moreover, the hypophagic effect of Cpd 1 is dependent on NOP receptors.Grant Funding Source: Eli Lilly and Company

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.